Evidence map›Paper›PMID 41998432›Full record

ArticleThe AAPS journal2026

Integrating In-vitro Permeability Assays within PBPK Modeling to Predict CNS Distribution of Standard and Engineered Antibodies.

Seunghyun Kim, Etienne Lessard, Binbing Ling, Kerry Rennie, Arsalan Haqqani, Anil R Maharaj

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Seunghyun KimFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Bristish Columbia, V6T 1Z3, Canada.ORCID 0009-0001-4392-0128
Etienne LessardHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canada.ORCID 0000-0002-4431-6475
Binbing LingHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canada.ORCID 0009-0000-6051-9590
Kerry RennieHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canada.ORCID 0000-0001-9216-2514
Arsalan HaqqaniHuman Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, K1A 0R6, Canada.ORCID 0000-0003-2454-8989
Anil R MaharajFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Bristish Columbia, V6T 1Z3, Canada. anil.maharaj@ubc.ca.ORCID 0000-0002-0475-6265

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The typically low, molecule-dependent permeability of antibodies across the blood-brain barrier (BBB) has driven the development of engineered constructs with optimized BBB transcytosis to facilitate efficient brain delivery. Physiologically-based pharmacokinetic (PBPK) modeling provides a framework to predict brain disposition and inform drug development; however, current models lack true a priori predictive capability and remain dependent on in-vivo data. In-vitro brain endothelial cell permeability (P

Indexed as

Antibodies, MonoclonalBlood-Brain BarrierBrainModels, BiologicalAnimalsBiological TransportEndothelial CellsHumansPermeabilityRatsTissue DistributionAntibodies, MonoclonalantibodiesbrainCSFPappPBPK model

Identifiers

PMID41998432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.